The Hepatic Encephalopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatic Encephalopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Hepatic Encephalopathy by 13 companies/universities/institutes. The top development phase for Hepatic Encephalopathy is phase ii with seven drugs in that stage. The Hepatic Encephalopathy pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hepatic Encephalopathy pipeline products market are: Neuropathix, ASKA Pharmaceutical and Lipocine.

The key targets in the Hepatic Encephalopathy pipeline products market include DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6), DNA Directed RNA Polymerase Subunit Beta (RNA Polymerase Subunit Beta or Transcriptase Subunit Beta or rpoB or EC 2.7.7.6), and DNA Gyrase (EC 5.99.1.3).

The key mechanisms of action in the Hepatic Encephalopathy pipeline product include DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Inhibitor with two drugs in Pre-Registration. The Hepatic Encephalopathy pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Hepatic Encephalopathy pipeline products market including Small Molecule, and Biologic.

Hepatic Encephalopathy overview

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics), and hypoxia.

For a complete picture of Hepatic Encephalopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.